Ono Pharmaceutical Co., Ltd. (4528) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 43 PAGES: 39

More Info
									            Ono Pharmaceutical Co., Ltd. (4528) - Financial and Strategic SWOT
                                    Analysis Review
        Reference Code: GDPH31988FSA                                                                                          Publication Date: APR 2013

          8-2, Kyutaromachi 1-chome                          Phone             +81 6 62635670                   Revenue          145,778 (million JPY)
          Chuo-ku, OSK                                       Fax                                                Net Profit       24,361 (million JPY)
          541-8564                                           Website           www.ono.co.jp                    Employees        2,492
                                                                               4528 [Osaka           Stock                       Pharmaceuticals           &
          Japan                                              Exchange                                           Industry
                                                                               Exchange]                                         Healthcare

       Company Overview
       Ono Pharmaceutical Co. Ltd. (Ono Pharmaceutical) is a pharmaceutical company. The company develops and markets drugs for
       prostaglandins (PG), enzyme inhibition and other specialized purposes. The company is specialized in the production and sale of
       prescription pharmaceuticals and diagnostic reagents. It has research expertise in major fields namely prostaglandins, enzyme
       inhibition, and neuroscience, among others.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Ono Pharmaceutical Co., Ltd., SWOT Analysis
         Gyo Sagara                          Chief Executive Officer                  Strengths                              Weaknesses
         Hiroshi Awata                       Director
                                                                                      Wide Array of Products                 Discontinuation of Drug
         Kazuhito Kawabata, Ph.D.            Director                                                                        Development
                                                                                      Strong Research Infrastructure
         Shinji Fujiyoshi                    Director
         Kei Sano                            Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Strategic Agreements                   Uncertain R&D Outcomes
       Share Data
                                                                                      New Product Launches                   Competitive Environment
         Ono Pharmaceutical Co., Ltd.
        Share Price (JPY) as on 29-Mar-                                5,730
        2013                                                                         Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        EPS (JPY)                                                     229.77
        Market Cap (million JPY)                                    607,477
        Enterprise Value (million JPY)                              591,194
        Shares Outstanding (million)                                     106
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 07, 2013         Receptos Determines New GPCR Structure,
                                                                                                           Achieves Key Milestone In Collaboration With
                                                                                                           Ono Pharma
                                                                                      Jan 11, 2013         Evotec Achieves Milestone In Drug Discovery
                                                                                                           Collaboration With Ono Pharma
                                                                                      Nov 05, 2012         Ono Pharma Reports Revenue Of JPY71.1
                                                                                                           Billion In H1 Fiscal 2013
                                                                                      Oct 04, 2012         Ono Pharma Conducts First Microdosing
                                                                                                           Study Using New Drug Candidate
       Source: Annual Report, Company Website, Primary and Secondary                 Source: Annual Report, Company Website, Primary and Secondary Research,
       Research, GlobalData                                                          GlobalData




Ono Pharmaceutical Co., Ltd. (4528) - Financial and Strategic                                                                  Reference Code: GDPH31988FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Ono Pharmaceutical Co., Ltd. - Key Facts ......................................................................................................................................... 5
       Ono Pharmaceutical Co., Ltd. - Key Employees ................................................................................................................................ 6
       Ono Pharmaceutical Co., Ltd. - Key Employee Biographies .............................................................................................................. 7
       Ono Pharmaceutical Co., Ltd. - Major Products and Services............................................................................................................ 8
       Ono Pharmaceutical Co., Ltd. - Pharmaceutical Pipeline Products Data ........................................................................................... 9
          Ono Pharmaceutical Co., Ltd., Pipeline Products by Therapy Area................................................................................................ 9
          Ono Pharmaceutical Co., Ltd., Pipeline Products by Development Phase ................................................................................... 10
       Ono Pharmaceutical Co., Ltd. - History ............................................................................................................................................ 12
       Ono Pharmaceutical Co., Ltd. - Company Statement....................................................................................................................... 16
       Ono Pharmaceutical Co., Ltd. - Locations And Subsidiaries ............................................................................................................ 17
          Head Office ................................................................................................................................................................................... 17
          Other Locations & Subsidiaries ..................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 19
       Ono Pharmaceutical Co., Ltd. - Business Description ...................................................................................................................... 19
       Ono Pharmaceutical Co., Ltd. - SWOT Analysis .............................................................................................................................. 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          Ono Pharmaceutical Co., Ltd. - Strengths .................................................................................................................................... 20
             Strength - Wide Array of Products ............................................................................................................................................. 20
             Strength - Strong Research Infrastructure................................................................................................................................. 20
             Strength - Increase in Sales ...................................................................................................................................................... 20
          Ono Pharmaceutical Co., Ltd. - Weaknesses ............................................................................................................................... 21
             Weakness - Discontinuation of Drug Development ................................................................................................................... 21
          Ono Pharmaceutical Co., Ltd. - Opportunities .............................................................................................................................. 21
             Opportunity - Strategic Agreements .......................................................................................................................................... 21
             Opportunity - New Product Launches........................................................................................................................................ 21
             Opportunity - New Approvals .................................................................................................................................................... 21
          Ono Pharmaceutical Co., Ltd. - Threats........................................................................................................................................ 22
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 22
             Threat - Competitive Environment ............................................................................................................................................. 22
             Threat - Lengthy Regulatory Process ........................................................................................................................................ 22
       Ono Pharmaceutical Co., Ltd. - Key Competitors ............................................................................................................................. 23
       Section 3 – Company Financial Ratios ............................................................................................................................................. 24
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 24
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 24
       Performance Chart ........................................................................................................................................................................... 26
       Financial Performance...................................................................................................................................................................... 26
       Financial Ratios - Interim Ratios....................................................................................................................................................... 27
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 28
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 29
          Ono Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ............................................. 29
          Ono Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013............................................. 30


Ono Pharmaceutical Co., Ltd. (4528) - Financial and Strategic                                                                                                  Reference Code: GDPH31988FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Ono Pharmaceutical Co., Ltd., Recent Deals Summary ................................................................................................................... 31
       Section 5 – Company’s Recent Developments ................................................................................................................................ 32
          Ono Pharmaceutical Co., Ltd., Recent Developments .................................................................................................................. 32
             Mar 07, 2013: Receptos Determines New GPCR Structure, Achieves Key Milestone In Collaboration With Ono Pharma....... 32
             Jan 11, 2013: Evotec Achieves Milestone In Drug Discovery Collaboration With Ono Pharma ................................................ 32
             Nov 05, 2012: Ono Pharma Reports Revenue Of JPY71.1 Billion In H1 Fiscal 2013 ............................................................... 32
             Oct 04, 2012: Ono Pharma Conducts First Microdosing Study Using New Drug Candidate ..................................................... 33
             Sep 03, 2012: BioFocus And Ono Pharma Sign Drug Discovery Agreement To Develop New Drugs For CNS Disorder
								
To top